Unprofitable Biotech Firms Flood Hong Kong IPO Pipeline in January 2026

　　【Pharmaceutical Network Medical Stock MarketSince 2026, the Hong Kong stock IPO market has continued to boom, with particularly high enthusiasm in the pharmaceuticals industry. Recently, according to incomplete statistics, more than 10 public pharmaceutical companies have submitted listing applications to the Hong Kong Stock Exchange, including PrimeGene, Zenitar, Simcere ZM, Eternity Bioscience, and GEN HOUSE.
 

On January 21, PrimeGene Therapeutics Co., Ltd. submitted an application for listing on the Main Board of the Hong Kong Stock Exchange. Public information shows that it is a biotechnology company focusing on the field of immune inflammation, with core competencies in innovative original design and precise local delivery, deeply cultivating in the treatment of chronic inflammatory diseases.
 

The core product of the company, PG-011 (Pumexitinib), is available in two formulations: a gel for atopic dermatitis and a nasal spray for allergic rhinitis. Pumexitinib gel is the world's first JAK inhibitor gel for the treatment of atopic dermatitis. It has completed Phase III clinical trials for adult and adolescent patients aged 12 to 17 with atopic dermatitis and is expanding to children aged 2 to 11 with atopic dermatitis. In addition, the company also has a diversified portfolio of candidate products, including various products targeting pruritus, autoimmune kidney disease, glaucoma, and other conditions.
 

On January 16, GEN HOUSE submitted its listing application to the Main Board of the Hong Kong Stock Exchange. The prospectus shows that the company focuses on developing potential best-in-class targeted therapies in the field of oncology, with its core technology centered around the RAS signaling pathway and synthetic lethality mechanisms. Currently, the company has seven self-developed drug candidates, including four clinical-stage drugs, one drug approved for IND by the China National Medical Products Administration (NMPA) and the U.S. FDA, and two preclinical-stage drugs. The purpose of this listing is to advance its R&D and industrialization strategy.
 

On January 14, YinoMicro officially submitted its prospectus to the Hong Kong Stock Exchange. According to the prospectus, it is a biotechnology company focusing on the discovery, development, production, and commercialization of novel oncolytic immunotherapy and engineered exosome therapy. Currently, YinoMicro has two oncolytic immunotherapy products targeting solid tumors and five engineered exosome products in its pipeline. Notably, the company had previously submitted a listing application on June 25, 2025, which subsequently lapsed on December 25, 2025, due to the expiration of the six-month validity period of the prospectus.
 

On January 13, Zenitar submitted its prospectus to the Hong Kong Stock Exchange for a proposed IPO on the Main Board. It is a biotechnology company in the late clinical stage, focusing on the development of innovative therapies in the fields of hematological diseases, oncology, central nervous system, and immune/inflammatory diseases. To date, Zenitar's R&D pipeline includes eight products, including two core products that have entered the Phase III registrational clinical trial stage, two other clinical-stage drug candidates, and four preclinical-stage drug candidates.
 

　　……
 

Overall, at the beginning of 2026, there has been a rush of pharmaceutical companies submitting listing applications to the Hong Kong Stock Exchange. This is a strategic collective action by Chinese innovative drug companies, occurring at a time when the industry is entering a "harvest period" and the capital market is showing a "favorable window."
 

It is worth noting that among these companies, a considerable number are not yet profitable, including Yifang Biotherapeutics, Bright Biology, Zenitar, GeneInno, and Immvira. Most of these companies are Biotechs (oncology, autoimmune, gene therapy, small-molecule innovation, etc.), primarily in the mid-to-late clinical stages; some are in the early commercialization stage but still have high R&D investments and have not yet achieved scaled profitability. Industry insiders believe this aligns with Hong Kong's inclusive positioning for unprofitable biotech companies and reflects the current pharmaceutical innovation industry rule of "early investment, late monetization."
 

　　Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.